Skip to content
Open access

Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition

Sep 2026 · bioRxiv · 0 citations · 34 references
Medicine Biology

TL;DR

Inhibiting pan-RAS(on) RAS-GTP with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.

Read PDF

Similar papers

Open access Sep 2026

The small molecule inhibitor SU056-mediated targeting of YB1 inhibits the Rb pathway in triple negative breast cancer tumors

Background Triple-negative breast cancer (TNBC) tumors lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, limiting the availability of targeted therapeutic options. As a result, TNBC is characterized by a high propensity for metastasis, rapid recurrence, and poor overall prognosis. Despite...

Wei Wang, Yeaji Kim, Xiao-Tong Zhao et al. · 1 citation
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Review

the MET gene for the treatment of non-small-cell

This review will focus on the MET pathway and its role in resistance to EGFR TK (tyrosine kinase) inhibitors, the different strategies of its inhibition, and the potential approaches to overcoming acquired resistance.

F. Gelsomino, F. Facchinetti, E. Haspinger et al. · 0 citations
Review Open access Sep 2026

Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes

This review synthesizes preclinical and clinical evidence on daraxonrasib and related RAS(ON) inhibitors across RAS-mutant malignancies and provides a comprehensive framework for understanding the promise and challenges of pan-RAS inhibition in precision oncology.

Jiacheng Lou, Dan Zhang · 0 citations
Aug 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.

F. Facchinetti, L. Friboulet, L. Liao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.